Malvinder Mohan Singh, Group Chairman, Religare & Fortis Healthcare, is an entrepreneur known for his aggressive style of management who has set a scorching pace of growth and diversification for the group companies.

Prior to this, Malvinder was the Chairman, Managing Director and CEO of Ranbaxy Laboratories Ltd. Malvinder put Ranbaxy in a position of leadership and consummated over 14 inorganic deals across geographies in less than two years. He unlocked value in Ranbaxy’s business model and focused the company on future growth drivers by monetizing large on-going patent challenges, investing resources in high growth emerging markets and forging strategic research alliances with global big pharma. Malvinder is credited of have having successfully led the company through a cultural transformation initiating a series of enterprise wide people centric initiatives. Most recently, in a landmark deal, Malvinder spearheaded the coming together of Ranbaxy and Daiichi Sankyo, a leading Japanese innovator, to create a pharmaceutical powerhouse. This deal is widely acknowledged as a game changer by the global pharma industry with other companies now trying to replicate Malvinder’s success.

Malvinder is a member of the Young Global Leaders Forum (YGL), an initiative of the World Economic Forum (WEF). He is also a member of the board of visitors at the Fuqua School of Business, Duke University and serves on the board of the INSEAD Global India Council. A member of the Board of Trade, constituted by the Ministry of Commerce & Industry, Government of India, Malvinder advises the Government on critical Policy issues relating to the country’s Foreign Trade, with the objective of significantly advancing India’s exports. Malvinder is also a member of the Board of the Indian Council for Research on International Economic Relations (ICRIER)

Malvinder earned his MBA from the Fuqua School of Business, Duke University, USA, after graduating in Economics from the St Stephen’s College, New Delhi, India.